Kura Oncology (NASDAQ:KURA) Earns Market Outperform Rating from JMP Securities

Kura Oncology (NASDAQ:KURA)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a note issued to investors on Thursday,Benzinga reports. They currently have a $28.00 target price on the stock. JMP Securities’ price target indicates a potential upside of 223.70% from the stock’s current price.

A number of other analysts have also recently commented on KURA. Bank of America reduced their price objective on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, Scotiabank dropped their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Price Performance

Shares of NASDAQ:KURA opened at $8.65 on Thursday. The business has a 50-day simple moving average of $8.79 and a two-hundred day simple moving average of $15.11. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a market cap of $672.62 million, a price-to-earnings ratio of -3.67 and a beta of 0.78. Kura Oncology has a fifty-two week low of $6.98 and a fifty-two week high of $24.17.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter in the prior year, the company posted ($0.50) earnings per share. On average, analysts expect that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,255 shares of company stock valued at $100,739 over the last ninety days. 5.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently bought and sold shares of the business. Wealthfront Advisers LLC purchased a new position in shares of Kura Oncology in the 4th quarter worth $1,289,000. AlphaQuest LLC purchased a new position in Kura Oncology in the fourth quarter worth about $177,000. E Fund Management Co. Ltd. bought a new stake in Kura Oncology during the fourth quarter worth approximately $90,000. Charles Schwab Investment Management Inc. increased its stake in Kura Oncology by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 635,494 shares of the company’s stock worth $5,535,000 after acquiring an additional 10,542 shares during the last quarter. Finally, US Bancorp DE raised its position in Kura Oncology by 184.5% during the fourth quarter. US Bancorp DE now owns 22,104 shares of the company’s stock valued at $193,000 after purchasing an additional 14,335 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.